MET and non-small cell lung carcinoma: In NSCLC patients harboring MET mutations, the administration of selective MET-tyrosine kinase inhibitors (TKIs), such as capmatinib, tepotinib and savolitinib, or other TKIs covering MET mutations, such as crizotinib, has been proven in previous studies to achieve a satisfactory response [8–10].